

CHEST PAIN

Matthew Subramani, MD

Virginia Mason Department of Cardiology

Seattle, WA

May 20th 2023

AGENDA

- 1) Scope
- 2) Chest pain characteristics
- 3) Acute chest pain initial evaluation
- 4) Treatment of ACS
- 5) Treatment of stable chest pain
- 6) Non CAD cardiac pain

CHEST PAIN PREVALENCE

- 2nd most common emergency department visit chief complaint
 - >6.5 million visits per year
 - 4.7% of ED visit
- 4 million outpatient visits per year
- CAD affects >18.2 million adults
- CAD is leading cause of death at >365,000 annually
- But... In patients presenting to the ED with chest pain, only 5.1% have ACS

CHEST PAIN DIFFERENTIAL DIAGNOSIS

CAN'T MISS


- Coronary artery disease
- Pulmonary embolism
- Aortic dissection
- Esophageal Rupture
- Pericarditis/Myocarditis

COMMON ETIOLOGIES

- GI
 - GERD, PUD, pancreatitis
- Pulmonary
 - Pneumonia, pleural irritation
- MSK/chest wall
 - Costochondritis, chest wall trauma, Herpes zoster

ANGINAL CHEST PAIN CHARACTERISTICS

- Substernal pain, pressure, heaviness
- Onset with exertion or emotional stress
- Resolves with rest or nitroglycerin
- Not always!
 - Crescendo decrescendo symptoms
 - Consider dyspnea in Women and Diabetics
 - Pain radiation
 - Associated symptoms: diaphoresis, nausea



Pretest Probabilities of Obstructive CAD in Symptomatic Patients

(A) according to age, sex, and symptoms;

(B) according to age, sex, symptoms, and CAC

Age, y	Chest Pain		Dyspnea	
	Men	Women	Men	Women
30-39	≤4	≤5	0	3
40-49	≤22	≤10	12	3
50-59	≤32	≤13	20	9
60-69	≤44	≤16	27	14
70+	≤52	≤27	32	12

A Pretest probability based on age, sex, and symptoms



B Pretest probability based on age, sex, symptoms, and CAC score⁺



CAC 1-99 CAC ≥100-999 CAC ≥1,000

CHEST PAIN EVALUATION



The History is key!



EKG



Troponin



Stress Testing



Anatomical evaluation with CCTA vs Invasive
Coronary Angiography


CHEST PAIN EVALUATION

STABLE ANGINA


- Chronic stable or slowly progressive chest pain

ACUTE CORONARY SYNDROME

- Unstable Angina
- NSTEMI
- STEMI



Progression of human coronary atherosclerosis I



The background of the slide features a close-up, slightly blurred view of an electrocardiogram (ECG) strip. The grid is a light pink color, and the ECG trace is a dark blue line. The strip is oriented diagonally from the bottom-left towards the top-right. The text 'ACUTE CHEST PAIN EVALUATION' is centered in a white box on the right side of the slide.


ACUTE CHEST PAIN EVALUATION

- New onset or increasing angina that is frequent, longer in duration, or occurs with less exertion than previous angina
- Should be prepared to evaluate this in any setting
 - Clinic
 - Urgent Care
 - Emergency Department
 - Hospital

2021 ACC/AHA CHEST PAIN GUIDELINES CLASS I RECOMMENDATIONS


- Unless clearly noncardiac obtain EKG
- EKG should be obtained and evaluated for STEMI within 10 minutes of presentation regardless of the setting
 - If unable to do so, should be directed to a location that is able
- Patients with clinical ACS should be transferred to the ED by EMS
- If acute symptoms, a troponin should be obtained

STEMI



1. Men <40 V_2 and V_3 should be 0.25 mV (2.5 mm)
2. Men >40 should be 0.2 mV (2 mm) in leads V_2 and V_3
3. For women 0.15 mV (1.5 mm) in leads V_2 and V_3
4. 0.1 mV (1mm) in all other leads
5. Remember “1 and for V2-V3: 1.5, 2, 2.5”
6. Look for reciprocal changes!


STEMI Localization



Coronary Anatomy & ECG Leads


Lateral Leads	I, aVL, V5 - V6	LCx or Diagonal of LAD
Inferior Leads	II, III, aVF	RCA and/or LCx
Anterior/Septal Leads	V1 - V4	LAD

POSTERIOR MI



- ST depression in V2-3
- Tall, broad R waves ($> 30\text{ms}$) in V2-3
- Dominant R wave (R/S ratio > 1) in V2
- Upright terminal portions of the T waves in V2-3



DE WINTER'S SIGN




- Tall, prominent, symmetrical T waves in the precordial leads
- Upsloping ST segment depression $> 1\text{mm}$ at the J point in the precordial leads
- Absence of ST elevation in the precordial leads

WELLEN'S SIGN

- Type A: Biphasic T wave in V2-V3
- Type B: Deeply inverted T wave in V2-V3
- Not a STEMI equivalent but suggestive of very tight LAD disease



PACEMAKERS AND KNOWN LBBB



BIOMARKERS

- Should use Troponin T or Troponin I
 - >99% ULN signifies **myocardial injury**
 - A rise or fall indicates the injury is acute (vs chronic)
 - **Myocardial ischemia** is present when there is also chest pain, EKG changes or new wall motion abnormalities on echocardiogram
- High Sensitivity Troponin (hs-cTn) is preferred
 - More sensitive = higher NPV
- CK-MB and myoglobin are not useful
- If chest pain present for 3 hours and hs-cTn normal, ACS ruled out
- hs-cTn trend at 1, 2, or 3 hours
- Traditional Troponin assay trend at 3-6 hours



INITIAL CHEST PAIN EVALUATION SUMMARY

- History, history, history!
- Based on history, classify as cardiac, possible cardiac, or noncardiac
 - Avoid atypical chest pain
- Acute vs chronic symptoms
- For acute symptoms evaluate with EKG and Troponin
- Decide:
 - Stable Angina
 - ACS (STEMI, NSTEMI, UA)

HEART


HEART score for chest pain patients

H istory (Anamnesis)	Highly suspicious	2	
	Moderately suspicious	1	
	Slightly suspicious	0	
E CG	Significant ST-deviation	2	
	Non-specific repolarisation disturbance / LBBB / PM	1	
	Normal	0	
A ge	≥ 65 years	2	
	45 – 65 years	1	
	≤ 45 years	0	
R isk factors	≥ 3 risk factors <i>or</i> history of atherosclerotic disease	2	
	1 or 2 risk factors	1	
	No risk factors known	0	
T roponin	≥ 3x normal limit	2	
	1-3x normal limit	1	
	≤ normal limit	0	
Total			

Risk factors for atherosclerotic disease:

Hypercholesterolemia	Cigarette smoking
Hypertension	Positive family history
Diabetes Mellitus	Obesity (BMI>30)

HEART score reliably predicts endpoints



HEART	~ % pts	MACE/n	MACE	Death	Proposed Policy
0-3	32%	38/1993	1.9%	0.05%	Discharge
4-6	51%	413/3136	13%	1.3%	Observation, risk management
7-10	17%	518/1045	50%	2.8%	Observation, treatment, CAG

*MACE = Major Adverse Cardiac Event = Myocardial Infarction, PCI/CABG, all-cause death. Based on N=6174

Literature:

- Chest pain in the emergency room: value of the HEART score. Six AJ, Backus BE, Kelder JC. *Neth Heart J*. 2008;16:191-6.
- Chest pain in the emergency room: a multicenter validation of the HEART Score. Backus BE, Six AJ, Kelder JC, et al. *Crit Pathways in Cardiol*. 2010;9:164-9.
- A prospective validation of the HEART score for chest pain patients at the emergency department. Backus BE, Six AJ, Kelder JC, et al. *Int J Cardiol*. 2013;168:2153-8.
- The HEART score for the assessment of patients with chest pain in the emergency department. Six AJ, Cullen L, Backus BE, et al. *Crit Pathways in Cardiol* 2013;12:121-126.
- Impact of using the HEART score in chest pain patients at the emergency department: a stepped wedge, cluster randomized trial. Poldersvaart JM, et al. *Annals of Internal Medicine*. 2017. Epub ahead of print

Questions and comments:

Barbra Backus backus@heartscore.nl
 Jacob Six six@heartscore.nl
 Judith Poldersvaart poldersvaart@heartscore.nl

www.heartscore.nl

USE CLINICAL DECISION MAKING PATHWAYS

- Many Choices
 - HEART
 - TIMI
 - GRACE

STRESS TESTING PEARLS

- Use to diagnose CAD in intermediate to high probability patient
- Or used in patients with known CAD to confirm angina and localize ischemic territory

STRESS TESTING PEARLS

MODALITIES

- Plain EKG treadmill
- Stress Echocardiogram
- Nuclear Stress Testing (SPECT or PET)
- Cardiac MRI
 - Pharmacologic only

EXERCISE VS PHARMACOLOGIC

- All patient's that are able to ambulate should exercise
 - EKG changes
 - Blood pressure response
 - Functional Capacity
 - Duke Treadmill Score
- LBBB or RV paced should consider pharmacologic nuclear study
 - Abnormal septal activation can lead to false positives

EXERCISE TREADMILL TEST (ETT)

KEY POINTS

- All exercise studies require obtaining a target HR of 85% Age predicted maximum
 - $220 - \text{Age} = \text{Max HR}$

CONTRAINDICATIONS

- Resting ST segment abnormalities
- LVH
- LBBB
- Paced rhythm
- WPW pattern on EKG
- Resting BP $>220/110$

STRESS ECHOCARDIOGRAPHY

KEY POINTS

- No radiation
- Can assess for LV function and valvular disease at the same time

CONTRAINDICATIONS

- Not many contraindications to echocardiography
- Dobutamine (pharmacologic agent)
 - Ventricular arrhythmias
 - Ideally avoid with Afib
 - BP >220/110


NUCLEAR STRESS TEST

KEY POINTS

- PET provides better imaging than SPECT but is not widely available and is only pharmacologic
- Modality of choice for paced rhythms and LBBB

CONTRAINDICATIONS

- Uses Radiation
- Pharmacologic agent is typically adenosine or Regadenoson
 - Vasodilators
- Heart block
- Severe Aortic Stenosis
- Asthma/COPD with active wheezing
- Hypotensive (SBP <90 mmHg)




STRESS CARDIAC MRI

ADVANTAGES

- No radiation
- Accurate LV function and chamber size assessment
- Can assess for myocarditis



CONTRAINICATION




- Expensive and not widely available
- GFR <30
- Allergy to gadolinium
- Uses adenosine



WHAT ABOUT CCTA?

- Noninvasive way to define coronary anatomy
- In acute chest pain and can reduce the time to diagnosis
- Long term outcomes are similar to other stress test modalities
- Indications:
 - Lower risk patients to rule out ACS
 - Nondiagnostic stress test results
 - To define anatomy after a positive stress test in place of ICA
 - More on the ISCHEMIA trial later!
 - Avoid with known large coronary calcifications or prior PCI






BRIEF COMMENTS ABOUT STABLE ANGINA MANAGEMENT

- Aspirin
- High intensity statin
- Risk factor modification
 - HTN goal <130/80
 - Cholesterol
 - Smoking
 - DM
- Beta Blockers
- Calcium channel blockers
 - Diltiazem, Verapamil, Amlodipine
- Long acting nitrates
- Ranolazine 500-1000 mg BID
 - Avoid if cirrhosis
 - Monitor for QTc prolongation
- Who to revascularize?

ISCHEMIA TRIAL


In **stable** patients with at least moderate ischemia on a stress test, is there a benefit to adding cardiac catheterization and, if feasible, revascularization to optimal medical therapy?



Major Exclusion Criteria

- NYHA Class III-IV HF
- Unacceptable angina despite medical therapy
- EF < 35%
- ACS within 2 months
- PCI or CABG within 1 year
- eGFR <30 mL/min or on dialysis


A Primary Composite Outcome



No. at Risk	0	1	2	3	4	5
Conservative strategy	2591	2431	1907	1300	733	293
Invasive strategy	2588	2364	1908	1291	730	271

A

Source	OR (95% CI)	P Value
Hambrecht ¹⁵	1.02 (0.02-52.43)	.99
MASS II ¹³	0.76 (0.27-2.16)	.60
COURAGE ¹⁷	0.84 (0.61-1.18)	.32
BARI 2D ¹⁴	1.06 (0.71-1.58)	.78
FAME 2 ¹⁶	0.33 (0.03-3.16)	.33
Overall	0.90 (0.71-1.16)	.42





**ISCHEMIA RESULTS
(THIS IS NOT NEW!)**

NONCAD CHEST PAIN

PERICARDITIS

- Inflammation of the pericardial lining
- Etiology: Viral, TB, post cardiac surgery or catheter ablation, autoimmune diseases, malignancy, Dressler Syndrome, Uremia
- Pain characteristics:
 - Sharp/stabbing
 - Positional (sitting up lessens pain)
 - Pleuritic (worsens with inspiration)
- Diagnostic Criteria (2 of 4)
 - Chest pain
 - Pericardial friction rub
 - EKG changes
 - Pericardial Effusion
- Check troponin to evaluate for myocarditis




PR depression and ST elevation in V5



Reciprocal PR elevation and ST depression in aVR



Spodick sign: Downsloping TP segment



DRUG	DOSE	DURATION
Aspirin	750-1,000 mg every 8 h	1-2 weeks
Ibuprofen	600-800 mg every 8 h	1-2 weeks
Colchicine	0.5-1.2 mg in one or divided doses	3 months

Aspirin	750-1,000 mg every 8 h	Weeks-months
Ibuprofen	600-800 mg every 8 h	Weeks-months
Indomethacin	25-50 mg every 8 h	Weeks-months
Colchicine	0.5-1.2 mg in one or divided doses	At least 6 months
Prednisone	0.2-0.5 mg/kg/daily	Months
Anakinra	1-2 mg/kg/daily up to 100 mg/daily	Months
Rilonacept	320 mg once, then 160 mg weekly	Months
Azathioprine	1 mg/kg/daily up to 2-3 mg/kg/daily	Months
Methotrexate	10-15 mg weekly	Months
MMF	2,000 mg daily	Months
IVIGs	400-500 mg/kg/day	5 days

Pericardiocentesis

Pericardial window



PERICARDITIS TREATMENT

- Who to hospitalize?
 - Febrile, immunosuppressed, cardiac tamponade, failure to improve after 7 days of treatment
- If recurrent or refractory symptoms consider:
 - NSAID taper
 - ESR/CRP guided taper
 - Avoid steroids as first line treatment as risk of recurrence is high!

SUMMARY

- Start with a good chest pain history
- Is the pain acute or chronic
 - ACS vs stable angina?
- Know common EKG findings
- Use Clinical Decision Pathways
- Know the benefits and contraindications to different stress test modalities
- Don't forget about CCTA
- In stable patient's who needs invasive coronary angiography (cath)
 - ISCHEMIA Trial

QUESTIONS?